Literature DB >> 15037634

Activation of syntaxin 1C, an alternative splice variant of HPC-1/syntaxin 1A, by phorbol 12-myristate 13-acetate (PMA) suppresses glucose transport into astroglioma cells via the glucose transporter-1 (GLUT-1).

Takahiro Nakayama1, Katsuhiko Mikoshiba, Tetsuo Yamamori, Kimio Akagawa.   

Abstract

Syntaxin 1C is an alternative splice variant lacking the transmembrane domain of HPC-1/syntaxin 1A. We found previously that syntaxin 1C is expressed as a soluble protein in human astroglioma (T98G) cells, and syntaxin 1C expression is enhanced by stimulation with phorbol 12-myristate 13-acetate (PMA). However, the physiological function of syntaxin 1C is not known. In this study, we examined the relationship between syntaxin 1C and glucose transport. First, we discovered that glucose transporter-1 (GLUT-1) was the primary isoform in T98G cells. Second, we demonstrated that glucose uptake in T98G cells was suppressed following an increase in endogenous syntaxin 1C after stimulation with PMA, which did not alter the expression levels of other plasma membrane syntaxins. We further examined glucose uptake and intracellular localization of GLUT-1 in cells that overexpressed exogenous syntaxin 1C; glucose uptake via GLUT-1 was inhibited without affecting sodium-dependent glucose transport. The value of Vmax for the dose-dependent uptake of glucose was reduced in syntaxin 1C-expressing cells, whereas there was no change in Km. Immunofluorescence studies revealed a reduction in the amount of GLUT-1 in the plasma membrane in cells that expressed syntaxin 1C. Based on these results, we postulate that syntaxin 1C regulates glucose transport in astroglioma cells by changing the intracellular trafficking of GLUT-1. This is the first report to indicate that a syntaxin isoform that lacks a transmembrane domain can regulate the intracellular transport of a plasma membrane protein.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15037634     DOI: 10.1074/jbc.M314297200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Identification and characterization of syntaxin 1 antisense variants in Limulus polyphemus.

Authors:  Z Cao; Y Wang; B S McAdory; M D Kemp; M T Ivy; R F Newkirk; J G Townsel
Journal:  Cell Mol Neurobiol       Date:  2006-02       Impact factor: 5.046

2.  Syntaxin 5 interacts with presenilin holoproteins, but not with their N- or C-terminal fragments, and affects beta-amyloid peptide production.

Authors:  Kei Suga; Takami Tomiyama; Hiroshi Mori; Kimio Akagawa
Journal:  Biochem J       Date:  2004-08-01       Impact factor: 3.857

3.  Hypoxia enhances the replication of oncolytic herpes simplex virus.

Authors:  Manish K Aghi; Ta-Chiang Liu; Samuel Rabkin; Robert L Martuza
Journal:  Mol Ther       Date:  2008-10-28       Impact factor: 11.454

4.  Soluble syntaxin 3 functions as a transcriptional regulator.

Authors:  Adrian J Giovannone; Christine Winterstein; Pallavi Bhattaram; Elena Reales; Seng Hui Low; Julie E Baggs; Mimi Xu; Matthew A Lalli; John B Hogenesch; Thomas Weimbs
Journal:  J Biol Chem       Date:  2018-02-23       Impact factor: 5.157

5.  Increased expression of the tail-anchored membrane protein SLMAP in adipose tissue from type 2 Tally Ho diabetic mice.

Authors:  Xiaoliang Chen; Hong Ding
Journal:  Exp Diabetes Res       Date:  2011-07-13

6.  Alternative splicing of the human gene SYBL1 modulates protein domain architecture of Longin VAMP7/TI-VAMP, showing both non-SNARE and synaptobrevin-like isoforms.

Authors:  Marcella Vacca; Lara Albania; Floriana Della Ragione; Andrea Carpi; Valeria Rossi; Maria Strazzullo; Nicola De Franceschi; Ornella Rossetto; Francesco Filippini; Maurizio D'Esposito
Journal:  BMC Mol Biol       Date:  2011-05-24       Impact factor: 2.946

7.  VEGF-B signaling impairs endothelial glucose transcytosis by decreasing membrane cholesterol content.

Authors:  Christine Moessinger; Ingrid Nilsson; Lars Muhl; Manuel Zeitelhofer; Benjamin Heller Sahlgren; Josefin Skogsberg; Ulf Eriksson
Journal:  EMBO Rep       Date:  2020-05-24       Impact factor: 8.807

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.